U.S. Food Stock News

SoCalGas, a Sempra subsidiary, released a report indicating inflation adjusted residential natural gas rates were roughly 25% lower in 2023 than in 2000. The report highlights the role of natural gas infrastructure in helping keep energy affordable and maintaining reliability during periods of volatility. SoCalGas positions natural gas as an important support for California's transition to higher renewable energy use and grid stability. Sempra (NYSE:SRE), recently trading around $92.38,...

W. R. Berkley (WRB) opened 2026 with Q1 total revenue of US$3.7b, basic EPS of US$1.31 and net income of US$515.2m, with underwriting profitability reflected in a combined ratio of 90.7%. Over the past year, the company has seen total revenue move from US$13.6b to US$14.9b on a trailing twelve month basis, while trailing EPS shifted from US$4.39 to US$4.74. This gives a clear view of how the top and bottom line have tracked together as margins held in a tight band. See our full analysis for...

Target Hospitality (NasdaqCM:TH) announced a secondary offering of common stock by major shareholders. The offering has been priced, with all shares sold by existing holders and no proceeds going to the company. Underwriters received an overallotment option, which may increase the total number of shares sold into the market. Target Hospitality operates in specialty rental and services, focusing on housing and related solutions for customers that often require large scale, remote or project...

Elevance Health (ELV) has just posted Q1 2026 results with revenue of US$50.2b and basic EPS of US$8.00, setting the tone for how its profitability story is evolving this year. The company has seen quarterly revenue move from US$48.9b in Q1 2025 to US$50.2b in Q1 2026, while basic EPS over that span has shifted from US$9.64 to US$8.00, against a trailing twelve month EPS of US$23.59 that sits on revenue of US$200.4b. With trailing net margin at 2.6%, the latest numbers keep the focus firmly...

Masco’s latest quarter in focus Masco (MAS) opened 2026 with Q1 revenue of US$1,918 million and basic EPS of US$1.05, setting a clear marker for how the year is starting to shape up. Over recent quarters, revenue has moved between US$1,793 million and US$2,051 million while quarterly EPS has ranged from about US$0.80 to US$1.29, and on a trailing twelve month basis EPS sits at US$4.06 with revenue at US$7.7 billion, giving investors a broad view of earnings power across cycles. With net...

Why Nutanix is Back on Investor Radar Recent commentary around Nutanix (NTNX) has zeroed in on its high gross margin of 87.1%, strong free cash flow, and cash-heavy balance sheet, drawing extra attention ahead of the upcoming earnings release. For you as an investor, this mix of profitability metrics and an earnings catalyst raises practical questions about how Nutanix’s business model and current valuation might fit into a broader portfolio focused on software and cloud exposure. See our...

The United States market has shown robust performance with a 1.7% increase over the last week and a remarkable 34% rise over the past year, while earnings are anticipated to grow by 16% annually in the coming years. In this thriving environment, identifying high growth tech stocks involves focusing on companies that demonstrate strong innovation potential and scalability to capitalize on these favorable conditions.

Over the last 7 days, the United States market has risen by 1.7%, contributing to a remarkable 34% increase over the past year, with earnings anticipated to grow by 16% annually in the coming years. In such a thriving environment, identifying stocks that may be priced below their estimated value can present compelling opportunities for investors seeking potential growth and value.

The United States market has shown positive momentum, with a 1.7% increase over the last week and a substantial 34% rise over the past year, alongside an anticipated annual earnings growth of 16%. In this thriving environment, growth companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those closest to the business, aligning well with current market trends.

For investors considering whether Ternium at around US$43.21 offers value or is already fully priced, this article breaks down what the current share price may be implying about the company. The stock has returned 1.2% over the past week, 12.8% over the past month, 10.4% year to date, and 64.9% over the last year. These figures provide useful context before weighing up what you are paying today. Recent coverage of Ternium has focused on its role in the broader metals and materials sector and...

The market has climbed 1.7% in the last 7 days and an impressive 34% over the past year, with earnings forecasted to grow by 16% annually. Investing in penny stocks—typically associated with smaller or newer companies—can still open doors to growth opportunities, especially when these stocks are supported by strong financial health. This article explores several promising penny stocks that combine balance sheet strength with long-term potential for investors seeking underappreciated growth...

The United States market has shown robust performance, rising 1.7% over the past week and climbing 34% in the last year, with earnings projected to grow by 16% annually. In this dynamic environment, identifying lesser-known stocks with strong growth potential can offer unique opportunities for investors seeking to capitalize on emerging trends.

This article examines whether Science Applications International might represent value at its current share price by walking through what the numbers are actually indicating about the stock. With a share price of US$95.71 and a 16.5% gain over five years, recent returns have been softer, with the stock down 0.5% over the past week, 1.2% over the past month, 5.4% year to date and 19.0% over the last year. Recent headlines around Science Applications International have focused on its role as a...

If you are wondering whether Lam Research shares still offer value after a strong run, or if you are turning up late to the party, this breakdown can help you frame the risk and reward trade off more clearly. The stock closed at US$265.55 and has posted returns of 0.1% over 7 days, 13.8% over 30 days, 43.5% year to date, 300.9% over 1 year, 449.5% over 3 years and 339.0% over 5 years. Recent headlines around Lam Research have focused on its role in semiconductor equipment, its exposure to...

Wondering whether Valley National Bancorp at around US$13.25 is offering fair value or an appealing entry point? This article walks through what the current price could imply for you as a shareholder. The stock has moved 0.8% over the last 7 days, 10.4% over the past month, 13.3% year to date, 60.0% over 1 year and 78.5% over 3 years, compared with a 17.8% return over 5 years. Recent coverage has focused on how regional banks are being reassessed by investors, and how balance sheet strength,...

Medline stock snapshot after recent moves Medline (MDLN) has attracted fresh attention after recent trading, with the share price at $47.16 and single-day, week, and month returns of around 1%, 2%, and 11% respectively. See our latest analysis for Medline. Over the past month Medline has logged an 11.0% share price return and a 16.1% year to date share price return, suggesting near term momentum is firming even though very short term moves have been softer. If you are comparing Medline with...

Moody's (MCO) opened 2026 with Q1 revenue of US$2.1b and basic EPS of US$3.74, setting the tone for how its profitability story is developing against a US$466.72 share price. Over recent quarters, revenue has moved from US$1.67b in Q4 2024 to between US$1.89b and US$2.08b across the last five reported periods, while quarterly basic EPS ranged from US$2.18 to US$3.74, underscoring how earnings power has tracked alongside higher net income figures. With a trailing net margin cited at 31.7%, the...

Highwoods Properties (NYSE:HIW) has authorized a $250 million share repurchase program. The company plans to fund the buybacks through sales of non core assets in its portfolio. The move reflects a shift in how Highwoods is choosing to allocate capital between assets and its own shares. Highwoods Properties enters this announcement with its shares recently closing at $23.74. The stock is up 2.4% over the past week and 11.7% over the past month, while the year to date return stands at a...

EQT (EQT) kicked off Q1 2026 with revenue of US$3.6 billion and basic EPS of US$2.38, alongside trailing twelve month revenue of US$9.4 billion and EPS of US$5.31. This sets a clear earnings bar for investors tracking the story. Over recent quarters the company has seen revenue move from US$2.4 billion in Q1 2025 and US$1.8 billion in Q4 2024 to US$3.6 billion in the latest quarter. Basic EPS has increased from US$0.40 and US$0.70 in those same periods to US$2.38, putting the focus firmly on...

If you are wondering whether California Resources at around US$64.65 is still offering value or starting to look fully priced, this breakdown will help you make sense of what the current market price might be implying. The stock has been relatively flat over the last 7 days with a 0.4% decline, but over longer periods it has delivered returns of 1.3% over 30 days, 39.4% year to date, 91.4% over 1 year, 81.2% over 3 years and 207.3% over 5 years. Recent coverage of California Resources has...

Ardelyx (NasdaqGM:ARDX) appointed Felecia W. Ettenberg as Chief Legal Officer, succeeding Elizabeth Grammer. The transition follows Grammer’s 16 year tenure in the role. Ettenberg brings extensive legal and regulatory experience from a leading pharmaceutical company. Ardelyx focuses on therapies in the biopharmaceutical space, where regulatory scrutiny, patent protection, and compliance requirements shape how companies operate. A new Chief Legal Officer sits at the center of these issues,...

If you are wondering whether Merchants Bancorp at around US$49.43 is still attractively priced after its recent run, this article walks through what the current valuation might be telling you. Over the short term, the stock has posted returns of 5.5% over 7 days and 18.6% over 30 days, with longer term returns of 49.0% year to date and 53.5% over 1 year providing useful context for where sentiment currently sits. Recent company news, regulatory filings or sector updates help explain why...

If you are considering whether Century Communities at around US$63.82 represents value or risk, this breakdown can help you understand what you are actually paying for. The share price has recently been active, with returns of 8.5% over 7 days, 11.0% over 30 days, and 8.3% year to date. This may be of interest if you are tracking momentum and changes in sentiment. Recent coverage has focused on Century Communities as part of a broader look at US homebuilders, with attention on how individual...

GE HealthCare Technologies (NasdaqGS:GEHC) has dosed the first patient in its Phase 2/3 LUMINA trial for mangaciclanol, a manganese based MRI contrast agent. The agent holds FDA Fast Track designation and is being studied as a potential alternative to gadolinium based contrast agents. The company highlights potential benefits related to patient safety, supply reliability, and reduced reliance on rare earth elements. GE HealthCare enters this trial with its shares at $71.38 and a mixed...